methylphenidate has been researched along with Cardiovascular Diseases in 19 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs." | 2.49 | Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. ( Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013) |
| " A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50)." | 1.43 | Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. ( Park, BJ; Pratt, NL; Roughead, EE; Shin, JY, 2016) |
| " During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects." | 1.38 | Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. ( Bellgrove, MA; Cho, SC; Cummins, TD; Kim, BN; Kim, JW, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alrwisan, AA | 1 |
| Wei, YJ | 1 |
| Brumback, BA | 1 |
| Antonelli, PJ | 1 |
| Winterstein, AG | 3 |
| Aries, E | 1 |
| El Louali, F | 1 |
| Ovaert, C | 1 |
| Antel, J | 1 |
| Albayrak, Ö | 1 |
| Heusch, G | 1 |
| Banaschewski, T | 3 |
| Hebebrand, J | 1 |
| Guertin, J | 1 |
| LeLorier, J | 1 |
| Durand, M | 1 |
| Gow, R | 1 |
| Holbrook, A | 1 |
| Levine, M | 1 |
| Knecht, KR | 1 |
| Chen, CY | 1 |
| Bussing, R | 1 |
| Hartzema, AG | 1 |
| Shuster, JJ | 1 |
| Segal, R | 1 |
| Jackson, JW | 1 |
| Shin, JY | 1 |
| Roughead, EE | 1 |
| Park, BJ | 1 |
| Pratt, NL | 1 |
| Hennessy, S | 1 |
| Schelleman, H | 1 |
| Daniel, GW | 1 |
| Bilker, WB | 1 |
| Kimmel, SE | 1 |
| Guevara, J | 1 |
| Cziraky, MJ | 1 |
| Strom, BL | 1 |
| Cho, SC | 1 |
| Kim, BN | 1 |
| Cummins, TD | 1 |
| Kim, JW | 1 |
| Bellgrove, MA | 1 |
| Olfson, M | 1 |
| Huang, C | 1 |
| Gerhard, T | 1 |
| Crystal, S | 1 |
| Allison, PD | 1 |
| Marcus, SC | 1 |
| Cortese, S | 1 |
| Holtmann, M | 1 |
| Buitelaar, J | 1 |
| Coghill, D | 1 |
| Danckaerts, M | 1 |
| Dittmann, RW | 1 |
| Graham, J | 1 |
| Taylor, E | 1 |
| Sergeant, J | 1 |
| Kraut, AA | 1 |
| Langner, I | 1 |
| Lindemann, C | 1 |
| Petermann, U | 1 |
| Petermann, F | 1 |
| Mikolajczyk, RT | 1 |
| Garbe, E | 1 |
| Arcieri, R | 1 |
| Germinario, EA | 1 |
| Bonati, M | 1 |
| Masi, G | 1 |
| Zuddas, A | 1 |
| Vella, S | 1 |
| Chiarotti, F | 1 |
| Panei, P | 1 |
| Sussman, S | 1 |
| Pentz, MA | 1 |
| Spruijt-Metz, D | 1 |
| Miller, T | 1 |
| Langendijk, PN | 1 |
| Wilde, AA | 1 |
| Jaffe, RB | 1 |
| Bennett, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Pediatric Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Cohorts (ADHD): a Randomized, Sham-controlled Study.[NCT06069323] | 80 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for methylphenidate and Cardiovascular Diseases
| Article | Year |
|---|---|
Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
Topics: Adolescent; Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Blood Press | 2015 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure | 2013 |
Misuse of "study drugs:" prevalence, consequences, and implications for policy.
Topics: Adolescent; Adult; Amphetamines; Cardiovascular Diseases; Central Nervous System Stimulants; Emotion | 2006 |
Cardiac and vascular involvement in drug abuse.
Topics: Adult; Aneurysm, Infected; Arterial Occlusive Diseases; Arteriovenous Fistula; Cardiomyopathies; Car | 1983 |
15 other studies available for methylphenidate and Cardiovascular Diseases
| Article | Year |
|---|---|
Concomitant Use of Quinolones and Stimulants and the Risk of Adverse Cardiovascular Symptoms: A Retrospective Cohort Study.
Topics: Adolescent; Adult; Aged; Amphetamines; Anti-Bacterial Agents; Arrhythmias, Cardiac; Cardiovascular D | 2019 |
[ECG before administration of Ritalin
Topics: Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Electrocardiography; Humans; | 2017 |
Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; | 2014 |
Cardiovascular safety of stimulant medications.
Topics: Adolescent; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Humans; Methylphenida | 2015 |
Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervou | 2016 |
The cardiovascular safety of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimu | 2016 |
Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Case-Control Stu | 2016 |
Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit | 2010 |
Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Diseases; Child; Delay | 2012 |
Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Amphetamines; Angina Pectoris; Arrhythmias, Cardiac; Attention Deficit Disorder with Hyp | 2012 |
Encouraging news about ADHD drugs and heart risk in adults.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Ne | 2012 |
Comorbidities in ADHD children treated with methylphenidate: a database study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Case-Control Stu | 2013 |
Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2012 |
[Medication for ADHD and the risk of cardiovascular mortality].
Topics: Amphetamine; Arrhythmias, Cardiac; Attention Deficit Disorder with Hyperactivity; Cardiovascular Dis | 2006 |
The management of massive gastrointestinal bleeding in the aged patient.
Topics: Aged; Blood Volume Determination; Cardiovascular Diseases; Cerebrovascular Disorders; Chromium Isoto | 1967 |